Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19
Shots:
- The EUA is based on data from several clinical trials- including P-III trial evaluating REGEN-COV (SC injection or IV infusion) vs PBO in high-risk patients with COVID-19 for post-exposure prophylaxis. The trial is jointly run with the NIAID
- The results showed 81% reduction in the risk of symptomatic infections while 62% reduction in asymptomatic patients based on a post-hoc analysis
- Regeneron collaborates with Roche to increase global supply of the Ab cocktail & Roche is responsible for development and distribution outside the US. REGEN-COV is currently available in 20+ countries including U.S.- EU- India- Switzerland and Canada- and is also fully approved in Japan
to | Ref: Regeneron | Image: WRGB
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com